Retrospective analysis reveals long-term efficacy of galcanezumab for migraine prevention, indicating valuable real-world insights.
Galcanezumab is approved in the EU for migraine prophylaxis in adults; although its efficacy has been demonstrated in multiple phase 3 clinical trials, long-term real-world data remain limited. This Adis Summary of Research summarizes the long-term effectiveness of galcanezumab for migraine prophylaxis based on a retrospective observational cohort study from Italy.
No takes yet. Share an insight, caveat, or question.
Yahiya Y. Syed (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: